Lundbeck loses top-line terrain but surpasses expectations
Sales of the drug Northera, which is no longer protected by patents, plummeted in Lundbeck's first quarter, while most other key products surpassed analysts' forecasts. This means the firm brought in more revenue than the market expected.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Lundbeck maintains its guidance for 2021 since the company's first quarter ended significantly better than what the market had expected.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck: Pandemic and currency woes have led to setbacks
For subscribers
Lundbeck backs Trintellix with new data
For subscribers
Lundbeck eyes major breakthrough for brain diseases
For subscribers
.jpg&w=384&q=75)
